-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
A study published online by "Nature" Escape of SARS-CoV-2 501Y.
V2 from neutralization by convalescent plasma showed that antibodies extracted from the first wave of survivors of the new crown epidemic in South Africa are against a new variant of the epidemic in South Africa (501Y.
V2) The neutralization effect is poor.
In contrast, the plasma of the six recovered patients infected with the 501Y.
V2 variant virus in the second wave of South Africa can effectively neutralize the virus strains in the first wave.
These findings indicate that vaccines based on new variants of the new coronavirus may be effective against other types of new coronaviruses that are circulating.
The worrisome new variants of the new coronavirus appear to give these viruses an advantage over other strains.
The results of recent vaccine trials conducted by Novavax, Johnson & Johnson and AstraZeneca in South Africa show that the prevalence of the 501Y.
V2 variant, which has become the main epidemic virus strain in parts of South Africa, may reduce the effectiveness of the vaccine.
Understanding how antibodies from one variant fight another variant may help vaccine development.
Alex Sigal of the African Health Research Institute in Durban, South Africa, and his colleagues compared the neutralizing activity of the serum of survivors infected with different virus variants in the first wave of South Africa and the second wave of the current new crown epidemic.
They collected plasma from the 14 survivors of the first wave of the epidemic and sequenced the infected virus.
Only 1 of the 14 survivors had an obvious mutation (mutation type E484K) with the virus before, and none of them Infected with the new variant 501Y.
V2.
Then they repeated this process for the 6 second-wave survivors of the new crown epidemic, and found that all the survivors had been infected with the 501Y.
V2 variant. In laboratory tests, the plasma of the first wave of survivors (except for the one infected with E484K) had worse neutralizing activity against the 501Y.
V2 variant than the first wave of virus.
However, the serum of the survivors of the second wave of the epidemic can effectively neutralize the virus of the first wave.
The serum of recovered patients infected with E484K mutant virus showed much stronger neutralizing ability against the first wave of epidemic virus and 501Y.
V2 mutant virus.
However, the author pointed out that since this serum was all derived from a recovered patient, this One result is more difficult to interpret further.
The author concluded that the vaccine designed for 501Y.
V2 may also be effective against other new coronavirus variants.
©Nature Nature | doi: 10.
1038/s41586-021-03471-w
V2 from neutralization by convalescent plasma showed that antibodies extracted from the first wave of survivors of the new crown epidemic in South Africa are against a new variant of the epidemic in South Africa (501Y.
V2) The neutralization effect is poor.
In contrast, the plasma of the six recovered patients infected with the 501Y.
V2 variant virus in the second wave of South Africa can effectively neutralize the virus strains in the first wave.
These findings indicate that vaccines based on new variants of the new coronavirus may be effective against other types of new coronaviruses that are circulating.
The worrisome new variants of the new coronavirus appear to give these viruses an advantage over other strains.
The results of recent vaccine trials conducted by Novavax, Johnson & Johnson and AstraZeneca in South Africa show that the prevalence of the 501Y.
V2 variant, which has become the main epidemic virus strain in parts of South Africa, may reduce the effectiveness of the vaccine.
Understanding how antibodies from one variant fight another variant may help vaccine development.
Alex Sigal of the African Health Research Institute in Durban, South Africa, and his colleagues compared the neutralizing activity of the serum of survivors infected with different virus variants in the first wave of South Africa and the second wave of the current new crown epidemic.
They collected plasma from the 14 survivors of the first wave of the epidemic and sequenced the infected virus.
Only 1 of the 14 survivors had an obvious mutation (mutation type E484K) with the virus before, and none of them Infected with the new variant 501Y.
V2.
Then they repeated this process for the 6 second-wave survivors of the new crown epidemic, and found that all the survivors had been infected with the 501Y.
V2 variant. In laboratory tests, the plasma of the first wave of survivors (except for the one infected with E484K) had worse neutralizing activity against the 501Y.
V2 variant than the first wave of virus.
However, the serum of the survivors of the second wave of the epidemic can effectively neutralize the virus of the first wave.
The serum of recovered patients infected with E484K mutant virus showed much stronger neutralizing ability against the first wave of epidemic virus and 501Y.
V2 mutant virus.
However, the author pointed out that since this serum was all derived from a recovered patient, this One result is more difficult to interpret further.
The author concluded that the vaccine designed for 501Y.
V2 may also be effective against other new coronavirus variants.
©Nature Nature | doi: 10.
1038/s41586-021-03471-w
